NDA 214273 · Azurity
Zonisade
Zonisamide · Oral · Anti-epileptic Agent
Last checked: Nov 20, 2026Latest source record: Jul 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jul 15, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
79
22 Phase 3, 1 recruiting
FAERS reports
10,721
8,243 serious, 683 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 8, 2025.
ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years and older. ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older ( 1 ).
Mechanism: The precise mechanism(s) by which zonisamide exerts its anticonvulsant effects is unknown. Zonisamide may produce these effects through action at sodium and calcium channels. In vitro pharmacological studies suggest that zonisamide blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes. Other in vitro studies have demonstrated that zonisamide (10–30 µg/mL) suppresses synaptically-driven electrical activity without affecting postsynaptic GABA or glutamate responses (cultured mouse spinal cord neurons)...
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 15, 2022 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- ZONISADE · ZONISAMIDE 100MG/5ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zonisamide" as an intervention, any sponsor and status, largest first.
Eisai LimitedEisai
NCT00215592 · 1,000 participants · Start Oct 2005 · Primary completion Jul 2007
Drug: Zonegran · For: Epilepsy
Sites: Innsbruck, Austria; Dianalund, Denmark; Glostrup Municipality, Denmark · 33 sites in all
- Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With ObesityPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00709371 · 729 participants · Start Jul 2008 · Primary completion Apr 2009
Drug: Zonisamide SR placebo/ bupropion SR placebo; Zonisamide SR placebo/ bupropion SR 360 mg/day and 4 more · For: Obesity
Sites: Fairhope, Alabama; La Jolla, California; Denver, Colorado · 20 sites in all
- Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated ObesityPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00339014 · 611 participants · Start May 2006 · Primary completion Aug 2007
Drug: Zonisamide CR and Bupropion SR · For: Obesity
Sites: Fairhope, Alabama; Los Angeles, California; San Diego, California · 15 sites in all
- Zonisamide Versus Topiramate in MigrainePivotal-lookingCompleted
Kafrelsheikh UniversityAcademic, hospital or other
NCT06347497 · 600 participants · Start Apr 1, 2024 · Primary completion Apr 1, 2026
Drug: Zonisamide 50 MG; Topiramate 50 MG · For: Migraine
Sites: Kafr ash Shaykh, Egypt
- Zonisamide Versus Propranolol in MigrainePivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT06361446 · 600 participants (planned) · Start Mar 29, 2024 · Primary completion Mar 30, 2025
Drug: Zonisamide 50 MG; Propranolol · For: Migraine
Sites: Kafr ash Shaykh, Egypt
- A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial EpilepsyPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00477295 · 583 participants · Start May 2007 · Primary completion Dec 2010
Drug: Zonisamide; Carbamazepine · For: Epilepsy
Sites: Camperdown, Australia; Clayton, Australia; Fitzroy, Australia · 79 sites in all
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01713946 · 366 participants · Start Apr 29, 2013 · Primary completion Oct 25, 2017
Drug: RAD001; Placebo and 2 more · For: Tuberous Sclerosis Complex-associated Refractory Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00848549 · 295 participants · Start Oct 2008 · Primary completion Jun 2011
Drug: Zonisamide; Carbamazepine · For: Epilepsy
Sites: Camperdown, Australia; Bedford Park, Australia; Clayton, Australia · 133 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,397
- seizure1,228
- off label use819
- fatigue501
- somnolence478
- dizziness402
- nausea387
- fall370
- headache364
- condition aggravated362
- drug interaction336
- vomiting321
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 52 |
| 2006 | 99 |
| 2007 | 115 |
| 2008 | 139 |
| 2009 | 151 |
| 2010 | 165 |
| 2011 | 292 |
| 2012 | 320 |
| 2013 | 240 |
| 2014 | 292 |
| 2015 | 400 |
| 2016 | 544 |
| 2017 | 493 |
| 2018 | 674 |
| 2019 | 816 |
| 2020 | 726 |
| 2021 | 970 |
| 2022 | 968 |
| 2023 | 917 |
| 2024 | 881 |
| 2025 | 856 |
| 2026 | 582 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zonisade (Zonisamide)
2024 spending
$4.4M
Beneficiaries
515
3,923 claims
Per beneficiary
$8,571
$2.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $113,264 |
| 2023 | $2,053,224 |
| 2024 | $4,413,917 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.